XEOS Information

In cancer surgery, the goal is to remove the tumor completely in a single operation. Yet whether that succeeded is often only known days later, when the pathology report comes back. Positive margins, cancer cells at the edge of the removed tissue, remain a challenge across cancer surgery: around 20% in breast cancer surgery, up to 43% in head and neck cancer surgery and around 25% in radical prostatectomy. For many patients, this means a second operation or additional treatment, with added burden, delays and extra costs. XEOS mission is to close that information gap in the operating room. Our flagship technology, AURA 10®, is a mobile specimen PET-CT platform designed specifically for intraoperative use. By bringing high-resolution molecular and structural imaging of the entire surgical specimen directly into the operating room, AURA 10 provides actionable insights to support surgical decision-making while intervention is still possible. AURA 10 is clinically validated through the prospective, multicenter BrIMA study, published in JAMA Surgery. Conducted across six European breast cancer centers, BrIMA demonstrated the value of intraoperative specimen PET-CT in supporting margin assessment and surgical decision-making during breast-conserving surgery. On its primary endpoint in invasive ductal carcinoma, the success rate in addressing positive margins of the invasive component rose from 83.3% without intraoperative margin assessment to 95.2% when surgeons used specimen PET-CT imaging. Designed to integrate into the surgical workflow, AURA 10 delivers 3D PET-CT imaging in approximately 10 minutes, providing surgeons with additional information during the intraoperative decision window. With growing clinical evidence across breast, head & neck and prostate cancer, XEOS is working with leading surgical oncology centers across Europe and the US to advance the role of intraoperative molecular imaging. XEOS is headquartered in Ghent, Belgium. See more. Know more.